en · de · es · fr · pt
nad-notes.peptides6908.com › Guide › Background And Mechanism — Beginner to Advanced

Background And Mechanism — Beginner to Advanced

By Editorial Desk · published 2026-05-01 · last reviewed 2026-05-27 · Guide

Everything below concerns HPLC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Related pages on this site

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Supporting material

Fifth generation In the 1990s, the fifth generation of silicone-gel breast prosthesis contained a semi-solid silicone-gel with a viscosity that reduced the occurrence of filler leakage and the occurrence of the filler migration throughout the woman's body of any silicone-filler that leaked from the implant-pocket. The plastic surgery studies Experience with Anatomical, Soft Cohesive Silicone-gel Prosthesis in Cosmetic and Reconstructive Breast Implant Surgery (2004) and Cohesive Silicone-gel Breast Implants in Aesthetic and Reconstructive Breast Surgery (2005) reported lower incidence-rates of capsular contracture and lower incidence-rates of shell rupture, and rates of medical safety and technical efficacy greater than the rates of safety and efficacy of early-generation prosthetic breasts.

== Medical devices == A variety of medical devices are in use or under consideration for treatment of depression including devices that offer electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and cranial electrotherapy stimulation. The use of such devices in the United States requires approval by the U.S. Food and Drug Administration (FDA) after field trials. In 2010 an FDA advisory panel considered the question of how such field trials should be managed. Factors considered were whether drugs had been effective, how many different drugs had been tried, and what tolerance for suicides should be in field trials.

Helium has a valence of zero and is chemically unreactive under all normal conditions. It is an electrical insulator unless ionized. As with the other noble gases, helium has metastable energy levels that allow it to remain ionized in an electrical discharge with a voltage below its ionization potential. Helium can form unstable compounds, known as excimers, with tungsten, iodine, fluorine, sulfur, and phosphorus when it is subjected to a glow discharge, to electron bombardment, or reduced to plasma by other means. The molecular compounds HeNe, HgHe10, and WHe2, and the molecular ions He+2, He2+2, HeH+, and HeD+ have been created this way. HeH+ is also stable in its ground state but is extremely reactive—it is the strongest Brønsted acid known, and therefore can exist only in isolation, as it will protonate any molecule or counteranion it contacts. This technique has also produced the neutral molecule He2, which has a large number of band systems, and HgHe, which is apparently held together only by polarization forces. Van der Waals compounds of helium can also be formed with cryogenic helium gas and atoms of some other substance, such as LiHe and He2. Theoretically, other true compounds may be possible, such as helium fluorohydride (HHeF), which would be analogous to HArF, discovered in 2000. Calculations show that two new compounds containing a helium-oxygen bond could be stable. Two new molecular species, predicted using theory, CsFHeO and N(CH3)4FHeO, are derivatives of a metastable FHeO− anion first theorized in 2005 by a group from Taiwan.

Sources: en.wikipedia.org

Notes from published material

Dinosaurs belong to a group known as archosaurs, which also includes modern crocodilians. Within the archosaur group, dinosaurs are differentiated most noticeably by their gait. Dinosaur legs extend directly beneath the body, whereas the legs of lizards and crocodilians sprawl out to either side. Collectively, dinosaurs as a clade are divided into two primary branches, Saurischia and Ornithischia. Saurischia includes those taxa sharing a more recent common ancestor with birds than with Ornithischia, while Ornithischia includes all taxa sharing a more recent common ancestor with Triceratops than with Saurischia. Anatomically, these two groups can be distinguished most noticeably by their pelvic structure. Early saurischians—"lizard-hipped", from the Greek sauros (σαῦρος) meaning "lizard" and ischion (ἰσχίον) meaning "hip joint"—retained the hip structure of their ancestors, with a pubis bone directed cranially, or forward. This basic form was modified by rotating the pubis backward to varying degrees in several groups (Herrerasaurus, therizinosauroids, dromaeosaurids, and birds). Saurischia includes the theropods (exclusively bipedal and with a wide variety of diets) and sauropodomorphs (long-necked herbivores which include advanced, quadrupedal groups). By contrast, ornithischians—"bird-hipped", from the Greek ornis (ὀρνίς) meaning "bird" and ischion (ἰσχίον) meaning "hip joint"—had a pelvis that superficially resembled a bird's pelvis: the pubic bone was oriented caudally (rear-pointing).

As a member of Team X, Logan was given false memory implants. Eventually breaking free of this mental control, he joined the Canadian Defense Ministry. Logan was subsequently kidnapped by the Weapon X program, where he was held captive and made a subject of experiments; the program fused adamantium onto his bones, before he escaped. James and Heather Hudson helped him recover his humanity following his escape, and Logan began work as an intelligence operative for the Canadian government's Department H. He becomes Wolverine, one of Canada's first superheroes. In his first mission, he is dispatched to stop the destruction caused by a brawl between the Hulk and the Wendigo. Professor Charles Xavier recruits Wolverine to a new iteration of his superhero-mutant team, the X-Men. He competes with Cyclops for the affection of Jean Grey. While his teammates often distrust him, Wolverine is invaluable in rescuing the others and defeating their enemies, particularly in their conflict with the Hellfire Club; due to their influence, Jean transforms into the Dark Phoenix and apparently sacrifices herself, temporarily ending the love triangle involving her, Wolverine, and Cyclops. Wolverine becomes engaged to Mariko Yashida, a wealthy businesswoman whose father is head of the Clan Yashida criminal organization, and battles the Hand, a secret society of ninjas. However, she breaks off the engagement, under the influence of a member of the Hellfire Club. He battles Sabretooth, and discovers that he had multiple encounters with him that his traumatic amnesia concealed.

==== International ==== 4-AcO-DMT is not scheduled under any international drug schedules, including the United Nations 1971 Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research.

Sources: en.wikipedia.org

Further detail

Electron capture: the decay energy is 0.93 MeV and the decay product is uranium-236. This usually decays (with a half-life of 23 million years) to thorium-232. Beta emission: the decay energy is 0.48 MeV and the decay product is plutonium-236. This usually decays (half-life 2.8 years) to uranium-232, which usually decays (half-life 69 years) to thorium-228, which decays in a few years to lead-208. Alpha emission: the decay energy is 5.007 MeV and the decay product is protactinium-232. This decays with a half-life of 1.3 days to uranium-232. Neptunium-236 is a fissile material; it has an estimated critical mass of 6.79 kg (15.0 lb), though precise experimental data is not available (as sufficient material for criticality is not). 236Np is produced in small quantities via the (n,2n) and (γ,n) capture reactions of 237Np, however, it is nearly impossible to separate in any significant quantities from its parent 237Np. It is for this reason that despite its low critical mass and high neutron cross section, it has not been researched extensively as a nuclear fuel in weapons or reactors. Nevertheless, 236Np has been considered for use in mass spectrometry and as a radioactive tracer, because it decays predominantly by beta emission with a long half-life. Several alternative production routes for this isotope have been investigated, namely those that reduce isotopic separation from 237Np or the isomer 236mNp. The most favorable reactions to accumulate 236Np were shown to be proton and deuteron irradiation of uranium-238.

== Receptors and targets == The specific receptors for adropin are not yet fully elucidated, and this is an area of active research. However, studies suggest that adropin might exert its effects by interacting with certain cell surface receptors.

Most of Poland that was partitioned and annexed to Prussia in the late 18th-century was still part of Greater Germany at the close of World War I, the rest of the Kingdom of Poland being in Austria-Hungary. The portion in Germany included the region of Greater Poland, of which Poznań (Posen) was a major industrial city and its capital. The majority of the population was Polish (more than 60%) and hoped to be within the borders of the new Polish state.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

How should SR9009 be stored?

Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.

Network